Evidence map›Paper›PMID 20802204›Full record

ArticleBrain : a journal of neurology2010

Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis.

Sergio E Baranzini, Radhika Srinivasan, Pouya Khankhanian, Darin T Okuda, Sarah J Nelson, Paul M Matthews, Stephen L Hauser, Jorge R Oksenberg, Daniel Pelletier

Open access · bronzeAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 2 pooled it
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 2 syntheses or guidelines pooled it, 131 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. The Association of the Polymorphisms in theInternational journal of molecular sciences · 2023
    Article
  8. Review
  9. Review
  10. Article
  11. CaJournal of immunology (Baltimore, Md. : 1950) · 2022
    Article
  12. Review
  13. Review
  14. Steroid Sulfation in Neurodegenerative Diseases.Frontiers in molecular biosciences · 2022
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 3 countries.

Sergio E BaranziniDepartment of Neurology, School of Medicine, University of California-San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143-0435, USA. sebaran@cgl.ucsf.edu
Radhika Srinivasan
Pouya Khankhanian
Darin T Okuda
Sarah J Nelson
Paul M Matthews
Stephen L Hauser
Jorge R Oksenberg
Daniel Pelletier
University of California, San Francisco · USGlaxoSmithKline (United Kingdom) · GB

Funding

GENE LINKAGE STUDY OF MULTIPLE SCLEROSIS SIBLING PAIRSR01NS026799 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAUSER, STEPHEN L, OKSENBERG, JORGE R. · 1989 to 2018
$6.8M
Molecular and Genetic Predictors of Disability Progression in MSR01NS062885 · NINDS · YALE UNIVERSITY · PI PELLETIER, DANIEL · 2009 to 2013
$1.6M
NINDS NIH HHS R01 NS026799NINDS NIH HHS R01 NS062885NINDS NIH HHS R01 NS26799
6 · The paper itself

Abstract

Glutamate is the main excitatory neurotransmitter in the mammalian brain. Appropriate transmission of nerve impulses through glutamatergic synapses is required throughout the brain and forms the basis of many processes including learning and memory. However, abnormally high levels of extracellular brain glutamate can lead to neuroaxonal cell death. We have previously reported elevated glutamate levels in the brains of patients suffering from multiple sclerosis. Here two complementary analyses to assess the extent of genomic control over glutamate levels were used. First, a genome-wide association analysis in 382 patients with multiple sclerosis using brain glutamate concentration as a quantitative trait was conducted. In a second approach, a protein interaction network was used to find associated genes within the same pathway. The top associated marker was rs794185 (P < 6.44 x 10(-7)), a non-coding single nucleotide polymorphism within the gene sulphatase modifying factor 1. Our pathway approach identified a module composed of 70 genes with high relevance to glutamate biology. Individuals carrying a higher number of associated alleles from genes in this module showed the highest levels of glutamate. These individuals also showed greater decreases in N-acetylaspartate and in brain volume over 1 year of follow-up. Patients were then stratified by the amount of annual brain volume loss and the same approach was performed in the 'high' (n = 250) and 'low' (n = 132) neurodegeneration groups. The association with rs794185 was highly significant in the group with high neurodegeneration. Further, results from the network-based pathway analysis remained largely unchanged even after stratification. Results from these analyses indicated that variance in the activity of neurochemical pathways implicated in neurodegeneration is explained, at least in part, by the inheritance of common genetic polymorphisms. Spectroscopy-based imaging provides a novel quantitative endophenotype for genetic association studies directed towards identifying new factors that contribute to the heterogeneity of clinical expression of multiple sclerosis.

Indexed as

AdultAspartic AcidBrainComputer SimulationFemaleFollow-Up StudiesGene FrequencyGenetic VariationGenome-Wide Association StudyGenotypeGlutamic AcidHumansMagnetic Resonance ImagingMagnetic Resonance SpectroscopyMaleMiddle AgedAspartic AcidGlutamic AcidN-acetylaspartateOxidoreductases Acting on Sulfur Group DonorsSulfatasesSUMF1 protein, human

Identifiers

PMID20802204
PMCPMC2929334
OpenAlexW2045605305

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.